SLC5A2 and urinary tract infection: Concerning urinary tract infections, even if HR were lower, the use of SGLT2 inhibitors was associated with a significantly increased risk compared to DPP inhibitors (HR 1.57), sulfonylureas (HR 1.66) and thiazolidinediones (HR 1.69).